According to a media release issued yesterday, Myovant Sciences (based in Basel, Switzerland) has submitted a New Drug Application (NDA) for approval of its oral LHRH antagonist, relugolix, in the treatment of men with advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: agonist, LHRH, Myovant, oral, relugolix | 2 Comments »
A poster presentation given the other day at the annual meeting of the Canadian Urological Association addressed the relative cardiovascular risks of LHRH agonist and antagonist therapies. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, cardivascular, complication, LHRH, risk | Leave a comment »
Since 2007 a randomized clinical trial in the UK (the so-called PATCH trial) has been comparing the effectiveness and safety of transdermal estradiol patches to implants of an LHRH receptor agonist (goserelin acetate) in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen, deprivation, estradiol, LHRH, outcome, PATCH | Leave a comment »
A new paper from a panel of experts in the UK has suggested that the use of LHRH antagonists (e.g., degarelix) may be more appropriate than the use of LHRH agonists (e.g., leuprolide acetate of goserelin acetate) in some prostate cancer patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, cardiovascular, LHRH, risk | 3 Comments »
Today’s news contained items that run the spectrum from the clinical value of tomatoes and lycopene via the cardiovascular side effects of LHRH agonists and antagonists to the question of whether proton beam radiation therapy is really cost-effective. So here are the “news shorts” for the day: … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk, Treatment | Tagged: agonist, antagonist, cost-effectiveness, LHRH, lycopene, proton beam, PSA density, side effect, testosterone, tomato | 3 Comments »
One of our regular readers has asked us to comment on a paper suggesting the possibility of “significant improvement” in various outcomes for men initially treated with the LHRH antagonist degarelix as compared to the LHRH agonists leuprolide acetate and goserelin acetate. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, antagonist, benefit, Degarelix, LHRH, outcome, survival | 1 Comment »
According to a survey of 75 Canadian physicians, there is a degree of disagreement among these physicians about what they should tell their patients about the side effects known to be associated with the use of LHRH agonists as a form of androgen deprivation therapy (ADT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, LHRH, side effects | 20 Comments »
The full text of a recent review on the use of LHRH receptor agonists (e.g., leuprolide acetate, goserelin acetate) asnd LHRH receptor antagonists (e.g., degarelix) has recently been published by Shore et al. in Prostate Cancer and Prostatic Diseases. The full text of the article is also available on line on the Medscape Oncology web site.
Filed under: Management, Treatment | Tagged: agonist, antagonist, LHRH, receptor, review | 3 Comments »
A study just published in European Urology suggests that — in addition to all the other side effects associated with LHRH receptor agonist therapy — such therapy also induces a small but statistically significant increase in risk for biliary disease. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: agonist, bile, biliary, gallstone, LHRH, risk | 3 Comments »
The question of whether an LHRH antagonist (such as degarelix) is really a better first-line hormone therapy than an LHRH agonist (e.g., leuprolide acetate) is still not fully answered. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, Degarelix, leuprolide, LHRH | Leave a comment »
First-line androgen deprivation therapy (ADT) for a man with metastatic prostate cancer has long been been either surgical or medical castration. In the case of medical castatration, the form of medication most commonly used since the mid to late 1980s has been an LHRH agonist (e.g., leuprolide acetate). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, LHRH, suppression, testosterone | 2 Comments »
A new paper just published online in Urology suggests that intermittent and testosterone (T)-based LHRH regimens are less likely to be associated with early onset of castration resistance than traditional, continuous, calender-based regimens. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, castration-resistance, LHRH, monotherapy, regimen | 1 Comment »
When all the drugs in the same class have the same general clinical impact, this is known as a “class effect.” As an example, all statins (hydroxymethylglutaryl–coenzyme A reductase inhibitors) will lower risk for certain types of cardiovascular event because they lower levels of cholesterol. That is a “class effect.” … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: agonist, antagonist, GnRH, LHRH | 5 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 